Mode
Text Size
Log in / Sign up

Serotonergic antidepressants and prolactin-elevating antipsychotics are associated with higher burdens of sexual dysfunctionCertain medications for depression and psychosis can cause sexual issues

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that serotonergic antidepressants and prolactin-elevating antipsychotics are associated with higher rates of sexual dysfunction.

This narrative review explores the prevalence and impact of sexual dysfunction in patients treated with antidepressants and antipsychotics for depressive and psychotic disorders. The authors synthesize evidence regarding how specific pharmacological classes contribute to sexual dysfunction, noting that strongly serotonergic antidepressants and prolactin-elevating antipsychotics are associated with a higher burden of these symptoms.

In contrast, the review suggests that certain newer or prolactin-sparing compounds may have relatively more favorable profiles for patients. The authors emphasize that sexual dysfunction is a clinically significant issue that can negatively impact quality of life, intimate relationships, self-esteem, and long-term treatment adherence.

A primary challenge identified by the authors is the difficulty in distinguishing between impairment caused by the underlying illness and dysfunction emerging from pharmacotherapy, as symptoms may precede the initiation of medication. Clinical management should include baseline evaluations and tailored strategies such as drug selection, dose adjustment, switching, or adjunctive interventions to mitigate these effects.

How this fits prior evidence

This narrative review addresses a gap in clinical management by highlighting the specific risk profiles of different antidepressant and antipsychotic classes regarding sexual dysfunction. While previous coverage has identified various risks associated with mental health medications, such as the unresolved mechanisms of drug-induced osteoporosis, this review focuses specifically on the impact of serotonergic and prolactin-elevating agents on patient quality of life and treatment adherence.

Living with a mental health condition is hard enough without the added burden of physical side effects. For many people taking antidepressants or antipsychotics, changes in sexual function can hurt their self-esteem and damage intimate relationships. These issues are significant enough that they often lead people to stop taking their prescribed medications entirely.

Research shows that not all medications cause these problems equally. Drugs that strongly affect serotonin or increase a hormone called prolactin tend to have a higher risk of causing sexual dysfunction. On the other hand, some newer drugs or those that do not raise prolactin levels may have more favorable profiles for patients who are concerned about these specific side effects.

It is important to note that it can be hard for doctors to tell if these issues are caused by the medication or by the illness itself. Because of this complexity, experts suggest a careful approach. This includes checking for symptoms before starting treatment and then adjusting doses or switching medications to help patients stay on their treatment plan while maintaining their quality of life.

What this means for you:
Some antidepressants and antipsychotics cause sexual issues, but newer options may have fewer side effects.

Common questions

Do all antidepressants cause sexual problems?

Not all medications have the same effect. The research shows a higher risk of sexual dysfunction with drugs that strongly affect serotonin. Some newer medications or those that do not increase prolactin levels are reported to have more favorable profiles for patients.

How does this affect my treatment plan?

Because these issues can lead people to stop taking their medicine, doctors recommend a tailored approach. This may include adjusting your dose, switching to a different medication, or using other treatments to manage side effects while keeping you on your path to health.

How do doctors know if the medication is causing the problem?

It can be difficult for doctors to tell if sexual issues are caused by the illness itself or by the medication. Because of this, it is helpful to have a baseline evaluation before starting treatment so your doctor can monitor changes accurately.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Sexual dysfunction is a common and clinically significant problem in patients treated with antidepressants and antipsychotics, yet it remains under-recognized in routine psychiatric practice. Its relevance extends beyond tolerability, as it may adversely affect quality of life, intimate relationships, self-esteem, and long-term adherence. A major clinical and methodological challenge is that sexual dysfunction frequently precedes pharmacotherapy, particularly in depressive and psychotic disorders, making it essential to distinguish illness-related impairment from treatment-emergent dysfunction. This narrative review provides an integrated overview of sexual dysfunction associated with antidepressants and antipsychotics, with emphasis on mechanisms, clinical assessment, and management. We summarize current evidence on the comparative risk across major drug classes and selected individual agents, highlighting the generally higher burden associated with strongly serotonergic antidepressants and prolactin-elevating antipsychotics, as well as the relatively more favorable profiles of selected newer or prolactin-sparing compounds. We further examine the principal serotonergic, dopaminergic, endocrine, autonomic, and vascular mechanisms involved, and discuss their relevance to the different domains of sexual functioning. Finally, we review practical strategies for routine care, including baseline evaluation, direct questioning, validated rating instruments, prevention through drug selection, dose adjustment, switching, and adjunctive interventions. Sexual dysfunction should be regarded as a meaningful clinical outcome in psychopharmacology, and its systematic assessment should be incorporated into routine treatment planning and follow-up.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.